Navigation Links
Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease

THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ: AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists with expertise in clinical medicine, IBD biology, human genetics, genomic technology, and drug discovery to work together to help create a new world of therapeutic options for IBD patients.

"We are thrilled to be working together with our Amgen colleagues in this visionary collaboration," said Ramnik Xavier, chief of gastroenterology and director of the Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital and a senior associate member of the Broad Institute. "I look forward to a fruitful collaboration, translating discoveries of IBD genes and biology into novel drugs for IBD patients." 

IBD is well known to run in families, suggesting that genes play a significant role in the development and progression of disease. However, until recently, almost nothing was known about the specific genes and mechanisms that predispose — or protect — someone from developing the disorder. Scientists have now pinpointed more than 150 regions of the genome — up from two just a decade ago — that place a person at risk for developing IBD. Despite the recent progress in understanding the biology of IBD, there remains a critical need:  treatments that make use of scientists' new knowledge are urgently needed. While drugs developed over the last decade have led to some marked improvements in IBD treatment, the drugs are not always effective and can cause significant side effects in some patients.

"Current IBD treatment options are limited," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We believe this collaboration with Massachusetts General Hospital and the Broad Institute will help identify improved treatment options for these patients."

The MGH-Broad-Amgen collaboration will leverage the shared expertise of its participating scientists and partner institutions to discover and develop novel therapies for IBD. The effort will include collection and analysis of patient DNA samples to identify and further validate genetic targets, biological assays to probe gene function, and subsequent drug discovery and development activities. A joint steering committee will be formed to select and guide projects. Financial terms of the agreement were not disclosed.

About Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

About the Broad Institute of MIT and Harvard

The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.

Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Mass. General media contact
Sue McGreevey,, 617 724-2764

Broad Institute media contact
Nicole Davis,, 617 714-7152

Amgen media contact
Ashleigh Koss,, 805 313-6151





Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Announces Lifting of FDA Warning Letter Related to Burlington, Mass. Facility
2. Leading Pension Annuity Provider Legal & General, Celebrates 175 Years
3. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
4. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
5. Stocks Outperformed the Broader Markets: Facebook Inc, Twitter Inc, CF Industries Holdings, Green Mountain Coffee Roasters, Arca Biopharma
6. B. Braun to Showcase its Broad Pharmacy Portfolio at ASHP
7. Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
8. Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
9. Trovagene Announces Issuance of Broad MicroRNA Patent
10. Huahai and Oncobiologics Create Broad Biosimilars Partnership
11. Z-Medica Announces Expanded CE Indications for QuikClot Hemostatic Dressings Supporting Broader Use in Surgical Wound Care
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a case of mesothelioma ... signs of mesothelioma and push for a diagnosis, especially in people exposed to asbestos. ... here to read it now. , Researchers at Gifu Prefectural Tajimi Hospital ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may ... one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there ... save the expense of having to replace NuvaRings more often than necessary. As such, ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating ... of 30 (see Table 1-1 ). More than 3.7 billion people under the ... virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . ...
Breaking Medicine News(10 mins):